Combinatorial therapy for protein signaling diseases
    61.
    发明授权
    Combinatorial therapy for protein signaling diseases 有权
    组合治疗蛋白信号传导疾病

    公开(公告)号:US08168568B1

    公开(公告)日:2012-05-01

    申请号:US12581019

    申请日:2009-10-16

    IPC分类号: C40B30/06

    CPC分类号: G01N33/5041

    摘要: A method for selecting combinations of drugs for treatment of diseases that arise from deranged signaling pathways is disclosed. The method involves measuring the activity states for signaling proteins in a diseased cell and determining whether the activity states are different from the activity states observed for a reference cell such as a normal cell. Based on the observed differences, combinations of two or more drugs are selected to reduce these differences. Treatment of a subject with the combinations restores the activity states of the signaling proteins of the deranged disease-associated signaling pathways toward the activity states observed in the reference cell. Since the diseased cell and the reference cell can both be obtained from the same subject, combinations of drugs that specifically target patient-specific signaling derangements is possible.

    摘要翻译: 公开了一种用于选择用于治疗由紊乱信号传导途径引起的疾病的药物组合的方法。 该方法包括测量患病细胞中的信号蛋白的活性状态,并确定活性状态是否与观察到的参考细胞例如正常细胞的活性状态不同。 基于观察到的差异,选择两种或更多种药物的组合以减少这些差异。 用组合治疗受试者恢复了与参考细胞中观察到的活动状态相关的紊乱疾病相关信号通路的信号蛋白的活性状态。 由于患病细胞和参照细胞都可以从相同的受试者获得,所以特别针对患者特异性信号紊乱的药物的组合是可能的。

    REAL-TIME DELIVERY OF MEDICAL TEST DATA TO PORTABLE COMMUNICATIONS DEVICES
    62.
    发明申请
    REAL-TIME DELIVERY OF MEDICAL TEST DATA TO PORTABLE COMMUNICATIONS DEVICES 审中-公开
    医疗测试数据实时传递给便携式通信设备

    公开(公告)号:US20110208534A1

    公开(公告)日:2011-08-25

    申请号:US13026346

    申请日:2011-02-14

    IPC分类号: G06Q50/00 G06Q10/00

    CPC分类号: G06Q50/22 G16H10/40 G16H40/20

    摘要: The present invention relates to a system and method for real-time delivery of medical tests and related data from laboratories or similar sources to portable communication devices such as mobile phones, text-enabled pagers and web-enabled personal digital assistance (PDA's) and other WAP devices. The subject system enables physicians to access test results remotely as soon as they become available. Also, the system allows the physician to develop an electronic prescription and submit the electronic prescription to a pharmacy using the portable communications device.

    摘要翻译: 本发明涉及一种用于将实验室或类似来源的医学测试和相关数据实时传递到诸如移动电话,支持文本的寻呼机和具有网络的个人数字助理(PDA)等便携式通信设备的系统和方法。 WAP设备。 主题系统使医师能够在可用时立即远程访问测试结果。 此外,该系统允许医生开发电子处方,并使用便携式通信设备将电子处方提交给药店。

    TISSUE PRESERVATION AND FIXATION METHOD
    65.
    发明申请
    TISSUE PRESERVATION AND FIXATION METHOD 有权
    组织保存和固定方法

    公开(公告)号:US20100068690A1

    公开(公告)日:2010-03-18

    申请号:US12447773

    申请日:2007-10-26

    CPC分类号: G01N1/30 A01N1/00

    摘要: This invention relates, e.g., to a composition that, at room temperature, when contacted with a sample comprising phosphoproteins, can fix and stabilize cellular phosphoproteins, preserve cellular morphology, and allow the sample to be frozen to generate a cryostat frozen section suitable for molecular analysis. The composition comprises (1) a fixative that is effective to fix the phosphoproteins, and that has a sufficient water content to be soluble for a stabilizer and/or a permeability enhancing agent); (2) a stabilizer, comprising (a) a kinase inhibitor and (b) a phosphatase inhibitor and, optionally, (c) a protease (e.g., proteinase) inhibitor; and (3) a permeability enhancing agent (e.g. PEG). Methods are described for preserving phosphoproteins, using such a composition. Also described are endogenous surrogate markers for monitoring protein degradation, including the loss of posttranslational modifications (such as phosphorylation), e.g. the following removal of a cell or tissue from a subject; and exogenous molecular sentinels (e.g. phosphoproteins attached to magnetic nanoparticles) that allow one to evaluate the processing history of a cellular or tissue population sample.

    摘要翻译: 本发明涉及例如在室温下与包含磷蛋白的样品接触时可以固定和稳定细胞磷酸蛋白的组合物,保留细胞形态,并允许样品冷冻以产生适于分子的低温恒温器冷冻切片 分析。 组合物包含(1)固定磷酸蛋白有效的固定剂,并且其具有足够的水含量可溶于稳定剂和/或渗透性增强剂); (2)稳定剂,其包含(a)激酶抑制剂和(b)磷酸酶抑制剂和任选的(c)蛋白酶(例如蛋白酶)抑制剂; 和(3)渗透性增强剂(例如PEG)。 描述了使用这种组合物来保存磷蛋白的方法。 还描述了用于监测蛋白质降解的内源替代标记,包括翻译后修饰(例如磷酸化)的丧失,例如, 以下从受试者中除去细胞或组织; 和外源性分子前哨蛋白(例如连接到磁性纳米颗粒的磷酸蛋白),其允许评价细胞或组织群体样品的加工历史。

    Stat3 as a theranostic indicator
    66.
    发明申请
    Stat3 as a theranostic indicator 审中-公开
    Stat3作为指标

    公开(公告)号:US20080255243A1

    公开(公告)日:2008-10-16

    申请号:US12081290

    申请日:2008-04-14

    CPC分类号: G01N33/57415 G01N2800/52

    摘要: This invention relates, e.g., to a method for predicting the response of a subject having estrogen-receptor-positive breast cancer to an inhibitor of the estrogen signaling pathway (e.g. tamoxifen), comprising measuring in a cancer sample from the subject the level of phosphorylation, compared to a baseline value, of one or more of the following members of an interconnected intracellular signaling pathway: (a) 4EBP1, and/or (b) p70S6, and/or (c) STAT3, and/or (d) FAK, wherein a significantly elevated level of phosphorylation of 4EBP1, and/or p70S6 and/or STAT3, and/or a significantly decreased level of phosphorylation of FAK, compared to the baseline value, indicates that the subject is likely to be a non-responder to the inhibitor and/or has a poor prognosis. Additional members of the intracellular signaling pathway whose phosphorylation can be measured are also described. Also described is a method for treating breast cancer in a subject in need thereof, wherein the subject exhibits an elevated level of phosphorylation of these markers, comprising administering to the subject an effective amount of one or more inhibitors of members of the interconnected intracellular signaling pathway.

    摘要翻译: 本发明涉及例如用于预测具有雌激素受体阳性乳腺癌的受试者对雌激素信号通路抑制剂(例如他莫昔芬)的反应的方法,包括在受试者的癌症样品中测量磷酸化水平 (a)4EBP1和/或(b)p70S6和/或(c)STAT3和/或(d)FAK的一个或多个以下成员的基线值; 其中与基线值相比,4EBP1和/或p70S6和/或STAT3的磷酸化水平显着升高和/或FAK的磷酸化水平显着降低,表明受试者可能是非应答者 对抑制剂和/或预后不良。 还描述了可以测量其磷酸化的细胞内信号传导途径的其他成员。 还描述了在有需要的受试者中治疗乳腺癌的方法,其中所述受试者表现出这些标志物的磷酸化水平升高,包括向受试者施用有效量的一种或多种互连的细胞内信号传导途径的成员抑制剂 。

    Methods for the isolation and analysis of cellular protein content
    67.
    发明授权
    Methods for the isolation and analysis of cellular protein content 有权
    分离和分析细胞蛋白质含量的方法

    公开(公告)号:US06969614B1

    公开(公告)日:2005-11-29

    申请号:US09913667

    申请日:2000-02-16

    摘要: The present invention describes devices and methods for performing protein analysis on laser capture microdissected cells, which permits proteomic analysis on cells of different populations. Particular disclosed examples are analysis of normal versus malignant cells, or a comparison of differential protein expression in cells that are progressing from normal to malignant. The protein content of the microdissected cells may be analyzed using techniques such as immunoassays, 1D and 2D gel electrophoresis characterization, Western blotting, liquid chromatography quadrapole ion trap electrospray (LCQ-MS), Matrix Assisted Laser Desorption Ionization/Time of Flight (MALDI/TOF), and Surface Enhanced Laser Desorption Ionization Spectroscopy (SELDI). In addition to permitting direct comparison of qualitative and quantitative protein content of tumor cells and normal cells from the same tissue sample, the methods also allow for investigation of protein characteristics of tumor cells, such as binding ability and amino acid sequence, and differential expression of proteins in particular cell populations in response to drug treatment. The present methods also provide, through the use of protein fingerprinting, a rapid and reliable way to identify the source tissue of a tumor metastasis.

    摘要翻译: 本发明描述了用于对激光捕获显微切割细胞进行蛋白质分析的装置和方法,其允许对不同群体的细胞进行蛋白质组学分析。 特别公开的实例是正常与恶性细胞的分析,或从正常到恶性进展的细胞中差异蛋白表达的比较。 可以使用免疫测定,1D和2D凝胶电泳表征,Western印迹,液相色谱四极离子阱电喷雾(LCQ-MS),基质辅助激光解吸电离/飞行时间(MALDI / TOF)和表面增强激光解吸电离光谱(SELDI)。 除了允许直接比较来自相同组织样品的肿瘤细胞和正常细胞的定性和定量蛋白质含量之外,该方法还允许研究肿瘤细胞的蛋白质特征,例如结合能力和氨基酸序列,以及差异表达 蛋白质在特定的细胞群体响应药物治疗。 本方法还通过使用蛋白质指纹图谱提供了一种快速可靠的方法来鉴定肿瘤转移的源组织。